📊 ACET Key Takeaways
Is Adicet Bio, Inc. (ACET) a Good Investment?
Adicet Bio is a pre-revenue biopharmaceutical company with severe cash burn (-$97M FCF) and no commercial revenue generation, indicating an early-stage development company burning through equity. With only 38.9M in cash reserves against annual operating losses exceeding $122M, the company faces critical runway constraints and substantial dilution risk within 5 quarters at current burn rates. The company exhibits classic biotech mortality risk with negative profitability metrics (-73.4% ROE, -60.7% ROA) dependent on clinical development success with no proof of commercialization capability.
Adicet Bio’s fundamentals reflect a pre-revenue biotech with persistent operating losses, negative returns on assets and equity, and substantial free cash outflow. The balance sheet is currently clean and liquid, but the business lacks revenue support and is dependent on its cash runway to fund ongoing R&D and operations.
Why Buy Adicet Bio, Inc. Stock? ACET Key Strengths
- Strong liquidity position with 7.47x current ratio providing short-term operational flexibility
- Minimal debt burden (0.00x D/E) reducing financial leverage risk
- Equity-capitalized balance sheet ($159.2M stockholders equity) providing cushion against insolvency in near term
- Strong near-term liquidity with a 7.47x current and quick ratio
- Debt-free balance sheet reduces financial leverage risk
- Positive EPS year-over-year improvement indicates some loss compression
ACET Stock Risks: Adicet Bio, Inc. Investment Risks
- Critical cash burn rate of $97M annually with only $38.9M in cash (approximately 4.8 months runway) necessitating immediate financing or partnership
- Zero revenue generation indicating pre-commercialization stage with binary outcome risk dependent on clinical trial success
- Substantial ongoing operating losses (-$122.1M operating income) with no clear path to profitability visible in current financial trajectory
- Dilutive capital raises likely required given cash position, with 4 Form 4 filings suggesting insider transactions amid financial stress
- No revenue base, leaving the company entirely reliant on external capital or existing cash reserves
- High annual cash burn with negative operating cash flow and free cash flow
- Deeply negative profitability metrics, including operating income, ROE, and ROA
Key Metrics to Watch
- Cash runway and quarterly burn rate trajectory
- Clinical trial progress milestones for pipeline assets
- Capital raise activities and resulting dilution metrics
- Operating expense management and cash preservation efficiency
- Quarterly operating cash burn relative to cash and equivalents
- Evidence of revenue generation or sustained reduction in operating losses
Adicet Bio, Inc. (ACET) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.47x current ratio provides a solid financial cushion.
ACET Profit Margin, ROE & Profitability Analysis
ACET vs Healthcare Sector: How Adicet Bio, Inc. Compares
How Adicet Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Adicet Bio, Inc. Stock Overvalued? ACET Valuation Analysis 2026
Based on fundamental analysis, Adicet Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Adicet Bio, Inc. Balance Sheet: ACET Debt, Cash & Liquidity
ACET Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Adicet Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-21.33 indicates the company is currently unprofitable.
ACET Revenue Growth, EPS Growth & YoY Performance
Adicet Bio, Inc. Dividends, Buybacks & Capital Allocation
ACET SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Adicet Bio, Inc. (CIK: 0001720580)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACET
What is the AI rating for ACET?
Adicet Bio, Inc. (ACET) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACET's key strengths?
Claude: Strong liquidity position with 7.47x current ratio providing short-term operational flexibility. Minimal debt burden (0.00x D/E) reducing financial leverage risk. ChatGPT: Strong near-term liquidity with a 7.47x current and quick ratio. Debt-free balance sheet reduces financial leverage risk.
What are the risks of investing in ACET?
Claude: Critical cash burn rate of $97M annually with only $38.9M in cash (approximately 4.8 months runway) necessitating immediate financing or partnership. Zero revenue generation indicating pre-commercialization stage with binary outcome risk dependent on clinical trial success. ChatGPT: No revenue base, leaving the company entirely reliant on external capital or existing cash reserves. High annual cash burn with negative operating cash flow and free cash flow.
What is ACET's revenue and growth?
Adicet Bio, Inc. reported revenue of N/A.
Does ACET pay dividends?
Adicet Bio, Inc. does not currently pay dividends.
Where can I find ACET SEC filings?
Official SEC filings for Adicet Bio, Inc. (CIK: 0001720580) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACET's EPS?
Adicet Bio, Inc. has a diluted EPS of $-16.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACET a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Adicet Bio, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACET stock overvalued or undervalued?
Valuation metrics for ACET: ROE of -73.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ACET stock in 2026?
Our dual AI analysis gives Adicet Bio, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACET's free cash flow?
Adicet Bio, Inc.'s operating cash flow is $-95.2M, with capital expenditures of $1.7M.
How does ACET compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -73.4% (avg: 15%), current ratio 7.47 (avg: 2).